# Vanda Pharmaceuticals (VNDA) — News

VNDA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/vnda/news

## Recent headlines

- [Vanda Pharmaceuticals - VQW-765 program on hold pending further analysis](https://www.ainvest.com/news/vanda-pharmaceuticals-vqw-765-program-hold-pending-analysis-2610) — AInvest Wire, Oct 14, 2026
  Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has placed its VQW-765 program on hold pending further analysis, according to internal updates and regulatory filings. The decision follows a strategic review of the program's clinical and commercial potential, as well as ongoing resource allocation…
- [Vanda Pharmaceuticals - Phase III study did not meet key secondary endpoint in full population](https://www.ainvest.com/news/vanda-pharmaceuticals-phase-iii-study-meet-key-secondary-endpoint-full-population-2610) — AInvest Wire, Oct 14, 2026
- [Vanda Pharmaceuticals - VQW-765 found safe and well tolerated in phase III study](https://www.ainvest.com/news/vanda-pharmaceuticals-vqw-765-safe-tolerated-phase-iii-study-2610) — AInvest Wire, Oct 14, 2026
  Vanda Pharmaceuticals Inc. (VandA) announced preliminary findings from its Phase III clinical trial evaluating the safety and tolerability of VQW-765, an investigational compound for the treatment of performance anxiety and social anxiety disorder. The trial, which compared VQW-765 to a placebo,…
- [Vanda Pharmaceuticals - Phase III study of VQW-765 did not meet primary endpoint in social anxiety disorder](https://www.ainvest.com/news/vanda-pharmaceuticals-phase-iii-study-vqw-765-meet-primary-endpoint-social-anxiety-disorder-2610) — AInvest Wire, Oct 14, 2026
  Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced that its Phase III clinical trial of VQW-765 for the treatment of social anxiety disorder did not meet its primary endpoint. The study, which evaluated the efficacy and safety of a single oral dose of VQW-765 compared to a placebo, failed to…
- [Vanda Pharmaceuticals - No new safety signals identified in phase III study for Hetlioz](https://www.ainvest.com/news/vanda-pharmaceuticals-safety-signals-identified-phase-iii-study-hetlioz-2609) — AInvest Wire, Sep 29, 2026
  Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has reported that no new safety signals were identified in a Phase III study evaluating Hetlioz (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD) in individuals who are completely blind. The open-label, long-term safety study,…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).